Metabolic & GLP-1

Incretin-based and metabolic peptides for weight management and glycemic control — the single highest-demand category. Unlike most peptides here, several are FDA-approved prescription drugs with substantial human clinical evidence.

Goal hub: Fat Loss

Peptides

• Tirzepatide — dual GIP/GLP-1 agonist; ~20% weight loss (Approved)
• Semaglutide — GLP-1 agonist; the anchor brand (Approved)
• Retatrutide — triple GLP-1/GIP/glucagon agonist (Clinical, investigational)
• AOD-9604 — GH-fragment fat-loss peptide (Preclinical)
• 5-Amino-1MQ — NNMT inhibitor for fat metabolism (Preclinical)

Compare

• Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · Semaglutide vs Retatrutide

---

← Home · See the Disclaimer